Post by marriott on Jan 28, 2024 0:04:58 GMT
NVAX closed on Friday, January 26, 2024, at $4.06 with a volume of 5,223,763 shares traded.
Let's look at what the Analysts stated 3 to 4 months ago:
Individual........ Company ..............Ranking .................target
Mayank Mamtani.... B.Riley Financial..... Buy .................... $12.00
Vernon Bernardino..H.C. Wainwright....... Buy .................... $35.00
Brendan Smith......TD Cowen.............. Hold ................... $8.00
Alec Stranahan.....Bank of America ...... Sell .........................
Current pipeline offered by Novavax:
Monovalent vaccine based on XBB.1.5
...On October 3, 2023 the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.
NVX-CoV2373
...Received Emergency Use Authorization from the US FDA and some other global authorizations. This is a protein-based vaccine targeting SARS-CoV-2, the virus that causes COVID-19.
Influenza (qNIV) vaccine
... Currently in Phase 2 clinical trial. qNIV targets seasonal flu and is designed using recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens.
COVID-Influenza combination vaccine
...Current in Phase 2 Clinical Trial. This vaccine uses the full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens.
Malaria Vaccine
...R21* is a protein-based vaccine developed by the University of Oxford.
On October 2, 2023, this vaccine received a WHO recommendation to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG). Authorized for use in several countries.
Now about the future.
Cash, cash equivalents, and restricted cash were $666 million as of September 30, 2023. This included sales of Novavax common stock at-the-market offerings during the third quarter of 2023, with net proceeds raised in the amount of $143 million.
In November 2023, the company stated the following priorities:
Priority #1: Deliver an Updated COVID-19 Vaccine for the Upcoming 2023 Fall Vaccination Season.
Priority #2: Reduce Rate of Spend, Manage Cash Flow, and Evolve Scale and Structure
Priority #3: Leverage Technology Platform, Capabilities, and Portfolio of Assets to Drive Additional Value Beyond Nuvaxovid.
The future vaccine environment:
I believe the COVID-related vaccines are excellent tools to prevent severe disease and death. Virus variants will encourage individuals to take the various booster doses. I was involved in a Novavax clinical trial and the results were personally outstanding.
If the concerns brought to light regarding the safety of mRNA continue to grow this will move more individuals to take and recommend a protein-based vaccine.
----
The next Conference Call will be held in a few months. Both the the time to the call and the cash runway are getting smaller. Let's see if Noavavx can now " stand and deliver ".
Let's look at what the Analysts stated 3 to 4 months ago:
Individual........ Company ..............Ranking .................target
Mayank Mamtani.... B.Riley Financial..... Buy .................... $12.00
Vernon Bernardino..H.C. Wainwright....... Buy .................... $35.00
Brendan Smith......TD Cowen.............. Hold ................... $8.00
Alec Stranahan.....Bank of America ...... Sell .........................
Current pipeline offered by Novavax:
Monovalent vaccine based on XBB.1.5
...On October 3, 2023 the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.
NVX-CoV2373
...Received Emergency Use Authorization from the US FDA and some other global authorizations. This is a protein-based vaccine targeting SARS-CoV-2, the virus that causes COVID-19.
Influenza (qNIV) vaccine
... Currently in Phase 2 clinical trial. qNIV targets seasonal flu and is designed using recombinant technology, with 4 forms of wild-type hemagglutinin (HA) protein from the influenza virus as antigens.
COVID-Influenza combination vaccine
...Current in Phase 2 Clinical Trial. This vaccine uses the full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens.
Malaria Vaccine
...R21* is a protein-based vaccine developed by the University of Oxford.
On October 2, 2023, this vaccine received a WHO recommendation to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG). Authorized for use in several countries.
Now about the future.
Cash, cash equivalents, and restricted cash were $666 million as of September 30, 2023. This included sales of Novavax common stock at-the-market offerings during the third quarter of 2023, with net proceeds raised in the amount of $143 million.
In November 2023, the company stated the following priorities:
Priority #1: Deliver an Updated COVID-19 Vaccine for the Upcoming 2023 Fall Vaccination Season.
Priority #2: Reduce Rate of Spend, Manage Cash Flow, and Evolve Scale and Structure
Priority #3: Leverage Technology Platform, Capabilities, and Portfolio of Assets to Drive Additional Value Beyond Nuvaxovid.
The future vaccine environment:
I believe the COVID-related vaccines are excellent tools to prevent severe disease and death. Virus variants will encourage individuals to take the various booster doses. I was involved in a Novavax clinical trial and the results were personally outstanding.
If the concerns brought to light regarding the safety of mRNA continue to grow this will move more individuals to take and recommend a protein-based vaccine.
----
The next Conference Call will be held in a few months. Both the the time to the call and the cash runway are getting smaller. Let's see if Noavavx can now " stand and deliver ".